Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 4/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21816700 | 0.89 | L3MBTL3 (0.43) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL28545335 | 0.88 | ATM (0.42) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL23931262 | 0.88 | CHRM4 (0.51) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL27038904 | 0.88 | CHRM4 (0.51) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL4201270 | 0.88 | CHRM4 (0.51) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL1023344 | 0.82 | SCN1A (0.53) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL1936279 | 0.81 | L3MBTL3 (0.40) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL1331414 | 0.80 | SCN1A (0.51) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL6954112 | 0.80 | SCN1A (0.51) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL28532026 | 0.80 | KMT2A (0.56) | SCN1ASCN2ASCN3AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110637015-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2019-12-31 | — | — | CN | claimed |
| CN-100421665-C | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-10-01 | — | — | CN | claimed |
| CN-1674906-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2005-09-28 | — | — | CN | claimed |
| CN-116354923-B | Nitrogen-containing heterocyclic compound and application thereof | 江苏恩华药业股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119522227-A | Macrocyclic compounds, pharmaceutical compositions and uses thereof | 贝达药业股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117980327-A | Specific coupling of antibodies | 杭州多禧生物科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117897149-A | 3, 4-methylenedioxymethamphetamine and related hallucinogens and uses thereof | 人类生物科学股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-114773254-B | Quaternary ammonium salt compound or salt thereof and application thereof, and method for distinguishing 2-hydroxyl-substituted fatty acid from 3-hydroxyl-substituted fatty acid | 中国科学院上海药物研究所 | 2024-02-13 | — | — | CN | disclosed |
| WO-2024017358-A1 | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 贝达药业股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-109111385-B | 5-HT 2A Receptor inhibitor and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116354923-A | Nitrogen-containing heterocyclic compound and application thereof | 江苏恩华药业股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-8461163-B2 | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461163-B2 | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
| EP-2443104-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | Eli Lilly and Company (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| WO-2010147917-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | WO | disclosed |
| CN-100421665-C | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-1674906-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | SCN1A 3413/4885SCN2A 4497/4885SCN3A 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.